Search

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Patient information

Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim

COPD_Patient_brochure.pdf

Boehringer Cares Patient Assistance Program Application - Spanish

Boehringer Cares Patient Assistance Program Application - English

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.

Christian Betz

Christian Betz shares his experience leading the process engineering team at Boehringer Ingelheim site in Biberach, Germany.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Biosimilars

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders

PI Update for Pradaxa® (dabigatran etexilate) | BI US

Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.

Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program

Boehringer Ingelheim and King’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophrenia

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Contact Us

Poultry

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers